Influential factors affecting the survival benefit of combined neoadjuvant therapy and esophagectomy in patients with esophageal cancer: an analysis based on the SEER database.

Background: Esophageal cancer (EC) is a major contributor to cancer-related deaths globally, with significant mortality rates. Neoadjuvant therapy (NAT), involving preoperative chemotherapy or radiation, aims to enhance outcomes in EC when combined with esophagectomy. However, its efficacy varies, necessitating identification of factors influencing survival benefits. This study aims to identify the factors influencing the survival benefit of NAT in patients with EC. Methods: The current retrospective cohort study collected data from the Surveillance, Epidemiology and End Results (SEER) database between 2004 and 2015. Propensity score matching (PSM) was used to balance baseline characteristics between the NAT and No NAT groups. A Cox model-based residual approach was applied to estimate the likelihood of survival benefit. Logistic regression was used to explore associated factors in the training cohort, and a nomogram was subsequently developed and validated. Results: In total, 2,755 patients were included in this study. Before PSM, the NAT group had a significantly longer median overall survival (mOS) than the No NAT group (31 Conclusions: This study identified clinical features potentially associated with survival benefit from NAT in patients with EC. The nomogram may serve as a reference tool to support treatment planning and patient selection in clinical practice.